4 reports

  • GASTRIC CANCER
  • BREAST CANCER

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest...

  • Cancer
  • Pharmaceutical
  • AbbVie Inc.
  • Amgen Inc.
  • Mersana Therapeutics, Inc.
  • Clinical Trials
  • Mersana Exercises Option for License Agreement with Millennium

Continued enrollment of the Phase ## dose escalation study of XMT-## in patients with advanced tumors expressing HER##, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer.

  • Cancer
  • Therapy
  • United States
  • Company
  • Mersana Therapeutics, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.